Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: A pilot study

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 10, 2013, Pages 1165-1169

  Huang, Zhanlian ^a,b   Deng, Hong ^a,b   Zhao, Qiyi ^a,b   Zheng, Yubao ^a,b   Peng, Liang ^a,b   Lin, Chaoshuang ^a,b   Zhao, Zhixin ^a,b   Gao, Zhiliang ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA VIRUS; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; PILOT STUDY; PRIORITY JOURNAL; SEROCONVERSION; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84883654897     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283612e95     Document Type: Article

References (12)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
2. Liaw Y-F. Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19:S128-S130.
3. Yang YF, Zhao W, Zhong Y.D., Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16:265-271.
4. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S., Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
5. Lau GK, Piratvisuth T, Luo K.X., Marcellin P., Thongsawat S, Cooksley G, et al Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
6. Lampertico P, Del Ninno E, Vigano M, Romeo R., Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756-763. (Pubitemid 36397385)
7. Sarin SK, Sood A, Kumar M., Arora A, Amrapurkar D, Sharma B.C., et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102:96-104. (Pubitemid 46072048)
8. Ter Borg M.J., van Zonneveld M, Zeuzem S, Senturk H., Akarca US, Simon C, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44:721-727. (Pubitemid 44433729)
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
10. Lok ASF, McMahon BJ AASLD Practice Guidelines: chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
11. Yuen MF, Lai CL Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 2007; 102:105-106.
12. Chan HL, Leung NW, Hui A.Y., Wong VW, Liew CT, Chim AM, et al A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250. (Pubitemid 40216241)